AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancerDavid S. Hong, A. Robert MacLeod, Nathan Fowler et al.|Science Translational Medicine|2015Cited by 438
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J. Reilley, David S. Hong, Patricia McCoon et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 286
Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in PrimatesJeffrey R. Crosby, Brett P. Monia, Ulla M. Marzec et al.|Arteriosclerosis Thrombosis and Vascular Biology|2013Cited by 128